To evaluate the efficacy of vitamin B6 supplementation on laboratory and clinical outcomes in patients with ulcerative colitis

in this double-blind placebo-controlled randomized trial ulcerative colitis Patients were randomly divided into two groups, intervention (usual treatment plus vitamin B6 40 mg / day) and placebo group (usual treatment plus placebo). The serum levels of inflammatory markers measured and compared at the beginning and the end of intervention.

overall forty patients were randomly selected to participate in this trial. Age range of participants was between 25-65 years and 3.43% of patients (13 cases) were male. Baseline characteristics of two groups were equal. The mean serum level of homocysteine after intervention in placebo and Vitamin B6 groups were 9.05±3.45 and 16.31±20.52 respectively (P= 0.205). There were no significant differences between serum levels of homocysteine, CRP (P=0.328), ESR (P=0.329), Calprotectin (P=0.683) and frequency of defecation after 6 months intervention in univariate analysis. In multivariate analysis frequency of defecation was significantly greater in vitamin B6 group in comparison with placebo group (P = 0.01).

We couldn’t find any significant effect of vitamin B6 supplementation on severity of ulcerative colitis and even defecation frequency in vitamin B6 group was greater.